Aduhelm, the first new Alzheimer’s drug in 18 years, could easily become the best-selling drug in Medicare, despite its potential massive cost and tremendous uncertainty about whether the drug even works.
Cancer is the second leading cause of death in the world. Almost everyone’s life is in some way or other affected by cancer. Yet, when faced with a cancer diagnosis, many of us will confront questions we had never before considered: Is cancer one disease, or many?
A team of researchers co-led by Guy Genin at the McKelvey School of Engineering has made a discovery about how tendon and bone attach in the shoulder joint, shedding light on rotator cuff injuries and how to treat them.
Researchers at Washington University School of Medicine have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy.
Irene Antony, a neuroscience major in Arts & Sciences at Washington University in St. Louis, won the Trainee Professional Development Award from the Society for Neuroscience.
Researchers at Washington University School of Medicine are joining scientists around the country to conduct a study aimed at understanding how prenatal factors and early life experiences influence brain development and behavior in young children.
Researchers at Washington University School of Medicine have found that multidrug-resistant bacteria and bacterial spores can be killed by ultrashort-pulse lasers. The findings could lead to new ways to sterilize wounds and blood products without damaging human cells.
Research from the lab of Renee J. Thompson in Arts & Sciences shows social media use associated with mixed outcomes when it comes to well-being during the pandemic.
Researchers at Washington University are receiving one of 19 grant awards that will support data science research and training activities in Africa. The researchers will focus on developing new training programs in health data science in Rwanda.
People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer’s COVID-19 vaccine, according to a study from Washington University School of Medicine.